HAIFA, Israel--(BUSINESS WIRE)--July 5, 2006--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced promising initial results of an animal model study using the company's innovative adjuvant cell therapy product known as PLX-1. PLX-1, by adding Mesenchymal Stromal Cells (MSC) during bone marrow transplant procedures that use umbilical cord blood (UCB) samples, is intended to offer a breakthrough solution to improved engraftment of blood-producing Hematopoeitic Stem Cells (HSC).
